When Should a Biotech Hire a CMC Regulatory Consultant?

Short answer: earlier than feels necessary, and always before a decision becomes expensive to reverse.

Most biotechs call a CMC regulatory consultant when something has already gone wrong: a clinical hold letter, a deficiency list, or a manufacturing change that nobody can show is comparable. At that point the consultant is doing damage control.

The better question is: which upcoming decisions will be costly to reverse, and does anyone on the team own them? That question points to specific triggers, not a calendar date.

Why "wait until Phase 2" is poor advice for CMC

Some advisers suggest bringing in regulatory support only once you have efficacy data. That may suit parts of clinical strategy. It does not suit CMC.

Your first clinical batch fixes things you will have to explain for the rest of the programme: the starting materials, the process, the analytical methods, the early specifications. Every later change must be justified against that baseline. By Phase 2, a weak baseline can't be fixed, only worked around, and that usually means comparability studies, delays, or repeated work.

This matters most for cell and gene therapies, where the process is the product. Small changes in a raw material, a culture step or a hold time can shift potency, phenotype or purity. You can only see the shift if you built the analytical capability to detect it.

The recognition test: seven triggers

You don't need a consultant on retainer from day one. You should engage one when any of these apply.

1. You are defining your Target Product Profile. The TPP is the earliest place CMC and clinical intent should meet. Which product attributes must be controlled to deliver the clinical profile you want? A consultant can help translate the TPP into candidate Critical Quality Attributes (CQAs) before you commit to an assay panel or a process.

2. You are about to choose a manufacturing process, platform or CDMO. Process and vendor choices are among the hardest to reverse. Regulatory input on starting materials, raw-material quality, scalability and tech transfer is much cheaper before a technology transfer than after.

3. You are building your analytical strategy, and potency is unresolved. For many cell therapies, potency is the bottleneck. A sophisticated assay that can't be tied to mechanism of action is worth less than a simpler one with demonstrated relevance. Decide your potency strategy early, not at the end.

4. You are designing the nonclinical programme. Toxicology and biodistribution studies are only persuasive if you can say which process and version produced the test material and how it compares with the intended clinical product. A consultant who sees both CMC and nonclinical can stop you commissioning an impressive study that doesn't answer the regulator's question.

5. You are preparing for a pre-IND, scientific advice or pre-CTA meeting. Health authority interactions are where your CMC position becomes visible. The questions you ask, and how you frame them, shape the feedback you get. This applies across FDA, EMA and MHRA, each with its own expectations and meeting formats.

6. You are writing, or about to write, your IND, CTA or IMPD quality sections. Module 3 and IMPD quality sections need a coherent story, not just correct data. Consultants are often brought in at this point, but the weak points were usually created earlier. If you engage at this stage, ask for a gap assessment first.

7. You are planning any manufacturing change, or investor due diligence is coming. Process changes, scale-up, site transfers and formulation updates all require a comparability argument. Investors and partners increasingly probe CMC readiness, and a traceable chain from TPP to clinical batch is a credible answer.

If two or more of these apply and nobody internally has done this before, you are already at the point where outside CMC expertise saves money.

Why timing matters more now

The regulatory landscape for advanced therapies is moving quickly. In 2026 FDA signalled a more flexible approach to CMC for cell and gene therapies and finalised guidance in May. It covers phase-appropriate manufacturing controls and, in some cases, smaller or evolving datasets early in development.

Flexibility does not mean fewer questions. It means more of the judgement sits with the sponsor: what you can defer, what you must justify now, and how you will build specifications and process validation over time. FDA has said sponsors should discuss their CMC approach with the agency before implementing it. Making those calls well requires people who have defended similar positions with regulators before.

What a good engagement looks like

The right model depends on your stage and in-house capability:

• Strategic gap assessment. A short, fixed-scope review of your CMC and nonclinical plan against likely regulator expectations. This is the best first step when budget is tight.

• Fractional or embedded support. A senior CMC regulatory lead working alongside your team for a defined number of days a month. This suits companies that need continuity but can't justify a full-time hire.

• Project-based authoring. Module 3 or IMPD drafting, briefing packages, and responses to agency questions.

• Lifecycle and comparability planning. Change strategy, comparability protocols and long-term specification planning.

When choosing a consultant, look for demonstrated experience with your modality, in your target regions, with authoring and agency interaction. Ask who will actually do the work. In larger firms, the senior person who sells the project is often not the one writing it. Ask also whether they will coach your team or simply deliver documents, because the best engagements leave you more capable.

The cost question

Consultants can seem expensive on a start-up budget. The real comparison is not consultant versus no consultant, but a small, well-timed investment versus the cost of repeating a study, delaying a first-in-human trial, or re-establishing comparability after a process change. A disciplined plan, one that builds the evidence chain from TPP to CQA to analytical strategy to process control to nonclinical relevance to clinical product, directs your limited cash at the experiments that reduce the most risk.

A simple rule of thumb

If a decision you are about to make would be expensive to reverse, and nobody on your team has made it before for your product type and regions, get a CMC regulatory consultant involved before you make it.